Maxim cuts Atossa Genetics to hold and removes its PT

Maxim Group downgraded Atossa Genetics (NASDAQ:ATOS) to “hold” from “buy” and removed its previous price target of $9 after the company reported results from its Phase 2 study evaluating topical endoxifen in patients with mammographic breast density (MBD). The stock was quoted at $2.57 in afternoon trading on June 27.

Read More
Stephen Kilmer
SVB Leerink cuts Aclaris Therapeutics to MP; PT to $4 from $13

SVB Leerink downgraded Aclaris Therapeutics (NASDAQ:ACRS) to “market perform” from “outperform” and slashed its price target to $4 from $13 after the failure of the company’s topical treatment for alopecia areata, an autoimmune disorder, resulting in unpredictable hair loss. The stock closed at $4.45 on June 26.

Read More
Abby Hardy